Phlebodia 600 mg (30 tablets)
- $49.50
The instruction for medical use
of FLEBODIA 600 medicine
the Trade name
of Flebodia 600
International unlicensed
names Diosmin Dosage Form
of the Tablet, film coated, 600 mg
Structure
One tablet contains
active agent - the diosmin purified (equivalent to diosmin anhydrous) 600 mg,
excipients: microcrystalline cellulose, talc, silicon dioxide colloidal anhydrous, kislotastearinovy,
structure of a cover: protective film Sepifilmtm 002 (gipromelloza, cellulose microcrystalline, stearate makrogol 400), SepisperstmAR dye 5523 pink (propylene glycol, gipromelloz, titan dioxide (E171), dye crimson
(E124), ferrous oxide red (E172), ferrous oxide black (E 172)), Opaglostm 6000 (wax palm, beeswax, gummilak, alcohol of 95%)
Description
of the Tablet of round shape, biconvex, film coated pink color.
Pharmacotherapeutic group
Cardiovascular system. Vazoprotektora. Kapillyarostabiliziruyushchy means. Bioflavonoids. Diosmin.
The ATX C05CA03 code
the Pharmacological
Pharmacokinetics Later properties of intake drug is quickly soaked up from digestive tract and is defined in blood plasma in 2 hours. The maximum concentration in blood plasma is reached in 5 hours after reception. Evenly is distributed and collects in all layers of a wall of venas cava and saphenas of the lower extremities, to a lesser extent - in kidneys, a liver, easy and other bodies. Selective accumulation of diosmin and/or its metabolites in venous vessels reaches a maximum by the 9th o'clock after reception and remains within 96 hours. It is removed mainly by kidneys (79%), also intestines (11%) and with bile (2.4%).
Pharmacodynamics
Venotoniziruyushchy action: reduces extensibility of veins, raises a venous tone, reduces venous stagnation, strengthens vasoconstrictive effect of adrenaline, noradrenaline.
One tablet contains 600 mg of diosmin that is optimum effective daily dose for venotoniziruyushchy action.
Angioprotektorny action: improves microcirculation, increases capillary resistance, reduces their permeability.
Action on lymphatic system: improves a lymphatic drainage, raises a tone and frequency of reduction of lymphatic capillaries, increases their functional density, reduces lymphatic pressure.
Has antiedematous effect. Reduces inflammation symptoms (dose-dependent effect).
Reduces adhesion of leukocytes to a venous wall and their migration in paravazalny fabrics, improves diffusion of oxygen and perfusion in fabric. Blocks development of free radicals, synthesis of prostaglandins and thromboxane.
In clinical trials it is confirmed: the decrease in average venous pressure in the system of superficial and deep veins of the lower extremities shown in double blind placebo the controlled research conducted under control of doppler sonography and also increase in systolic and diastolic arterial blood pressure at patients with postoperative orthostatic hypotension.
Indications
Treatment of symptoms of limfovenozny insufficiency of the lower extremities (feeling of heavy, fatigue, a raspiraniye in legs, the pain amplifying by the end of day, hypostases),
treatment of symptoms of acute hemorrhoids,
additional treatment at microcirculation disturbance.
The route of administration and doses
Drug is intended for intake.
Limfovenozny insufficiency of veins of the lower extremities
At chronic limfovenozny insufficiency appoint on 1 tablet a day it is desirable to food in the morning.
Usually the course of administration of drug makes 2 months.
Acute hemorrhoids and exacerbation of chronic hemorrhoids.
In acute hemorrhoids and exacerbation of chronic hemorrhoids drug is appointed by the first four days on 1 tablet 3 times a day at meal time, in the next three days on 1 tablet 2 times a day at meal time.
In case of repeated emergence of symptoms the course of treatment can be repeated according to the recommendation of the doctor.
Chronic hemorrhoids
After stopping of the sharp phenomena are recommended to continue administration of drug on 1 tablet of 1 times a day within 1-2 months.
If it is missed one or several administrations of drug, it is necessary to continue use of drug in the usual mode and in a usual dose.
Before use of drug it is necessary to consult with the doctor.
Side effects
Seldom
- hypersensitivity to drug components
- dispepsichesky disorders
- a headache
- allergic reactions
of the Contraindication
- hypersensitivity to drug components,
- children's age up to 18 years (experience of use is limited),
- during breastfeeding (experience of use is limited).
Medicinal interactions
of Clinically significant effects of interaction with other medicines it is not described.
Strengthening of vasoconstrictive effect of adrenaline and noradrenaline is possible.
Special instructions
In acute hemorrhoids the treatment has to be short-term.
Treatment of acute hemorrhoids can be carried out in a complex with other methods of treatment. In case symptoms do not disappear after the recommended course of treatment, it is necessary to consult with the expert who will pick up further therapy.
Presence of Ponso4R dye (E124) can lead ment of allergic manifestations.
Pregnancy and a lactation
Use during pregnancy is possible only |only| on doctor's orders when the expected advantage |self-interest| for mother exceeds potential risk for a fruit.
In pilot studies the teratogenic impact on a fruit was not revealed. So far in clinical practice there were no messages about cases of malformatsionny or fetotoksichesky action on a fruit at use of drug for pregnant women.
Due to the lack of data on penetration of drug into breast milk, administration of drug is not recommended to the feeding women.
There Is no feature of influence of drug on ability to run the vehicle or potentially dangerous mechanisms data on negative influence of drug on ability to run vehicles and other mechanisms
Overdose
Symptoms of overdose are not described.
A form of release and packing
On 15 or 18 tablets in planimetric cell packing from a film of polyvinylchloride and aluminum foil.
On 1, 2 and 4 (on 15 tablets) or on 1 (on 18 tablets) blister strip packagings together with the instruction for medical use place in a cardboard pack.
To Store storage conditions at a temperature not over 30C.
To store out of children's reach!
Not to apply a period of storage of 5 years after the expiration date specified on packing
Prescription status
Without prescription
the Producer Innotera Shuzi, Rue Rene Shantero, Shuzi-Sur-Cis, 41150, Valuar-sur-Cis, France
the Owner of the registration certificate
Innoter's Laboratory, France
the Name, the address and a contact information (phone, the fax, e-mail) of the organization in the territory of the Republic of Kazakhstan, the accepting claim (offer) on quality of medicines from consumers and responsible for post-registration observation of safety of medicine:
Representative office of Innotek Internasional Laboratory of S.A.S. in PK
050059, Republic of Kazakhstan, Almaty, Al-Farabi Ave., 17, Nurla Tau's business center, the block of 4 B, office 606, ph./fax: +7-727-311-09-71, +7-727-311-09-72, e-mail: innotech@innotech.kz
of FLEBODIA 600 medicine
the Trade name
of Flebodia 600
International unlicensed
names Diosmin Dosage Form
of the Tablet, film coated, 600 mg
Structure
One tablet contains
active agent - the diosmin purified (equivalent to diosmin anhydrous) 600 mg,
excipients: microcrystalline cellulose, talc, silicon dioxide colloidal anhydrous, kislotastearinovy,
structure of a cover: protective film Sepifilmtm 002 (gipromelloza, cellulose microcrystalline, stearate makrogol 400), SepisperstmAR dye 5523 pink (propylene glycol, gipromelloz, titan dioxide (E171), dye crimson
(E124), ferrous oxide red (E172), ferrous oxide black (E 172)), Opaglostm 6000 (wax palm, beeswax, gummilak, alcohol of 95%)
Description
of the Tablet of round shape, biconvex, film coated pink color.
Pharmacotherapeutic group
Cardiovascular system. Vazoprotektora. Kapillyarostabiliziruyushchy means. Bioflavonoids. Diosmin.
The ATX C05CA03 code
the Pharmacological
Pharmacokinetics Later properties of intake drug is quickly soaked up from digestive tract and is defined in blood plasma in 2 hours. The maximum concentration in blood plasma is reached in 5 hours after reception. Evenly is distributed and collects in all layers of a wall of venas cava and saphenas of the lower extremities, to a lesser extent - in kidneys, a liver, easy and other bodies. Selective accumulation of diosmin and/or its metabolites in venous vessels reaches a maximum by the 9th o'clock after reception and remains within 96 hours. It is removed mainly by kidneys (79%), also intestines (11%) and with bile (2.4%).
Pharmacodynamics
Venotoniziruyushchy action: reduces extensibility of veins, raises a venous tone, reduces venous stagnation, strengthens vasoconstrictive effect of adrenaline, noradrenaline.
One tablet contains 600 mg of diosmin that is optimum effective daily dose for venotoniziruyushchy action.
Angioprotektorny action: improves microcirculation, increases capillary resistance, reduces their permeability.
Action on lymphatic system: improves a lymphatic drainage, raises a tone and frequency of reduction of lymphatic capillaries, increases their functional density, reduces lymphatic pressure.
Has antiedematous effect. Reduces inflammation symptoms (dose-dependent effect).
Reduces adhesion of leukocytes to a venous wall and their migration in paravazalny fabrics, improves diffusion of oxygen and perfusion in fabric. Blocks development of free radicals, synthesis of prostaglandins and thromboxane.
In clinical trials it is confirmed: the decrease in average venous pressure in the system of superficial and deep veins of the lower extremities shown in double blind placebo the controlled research conducted under control of doppler sonography and also increase in systolic and diastolic arterial blood pressure at patients with postoperative orthostatic hypotension.
Indications
Treatment of symptoms of limfovenozny insufficiency of the lower extremities (feeling of heavy, fatigue, a raspiraniye in legs, the pain amplifying by the end of day, hypostases),
treatment of symptoms of acute hemorrhoids,
additional treatment at microcirculation disturbance.
The route of administration and doses
Drug is intended for intake.
Limfovenozny insufficiency of veins of the lower extremities
At chronic limfovenozny insufficiency appoint on 1 tablet a day it is desirable to food in the morning.
Usually the course of administration of drug makes 2 months.
Acute hemorrhoids and exacerbation of chronic hemorrhoids.
In acute hemorrhoids and exacerbation of chronic hemorrhoids drug is appointed by the first four days on 1 tablet 3 times a day at meal time, in the next three days on 1 tablet 2 times a day at meal time.
In case of repeated emergence of symptoms the course of treatment can be repeated according to the recommendation of the doctor.
Chronic hemorrhoids
After stopping of the sharp phenomena are recommended to continue administration of drug on 1 tablet of 1 times a day within 1-2 months.
If it is missed one or several administrations of drug, it is necessary to continue use of drug in the usual mode and in a usual dose.
Before use of drug it is necessary to consult with the doctor.
Side effects
Seldom
- hypersensitivity to drug components
- dispepsichesky disorders
- a headache
- allergic reactions
of the Contraindication
- hypersensitivity to drug components,
- children's age up to 18 years (experience of use is limited),
- during breastfeeding (experience of use is limited).
Medicinal interactions
of Clinically significant effects of interaction with other medicines it is not described.
Strengthening of vasoconstrictive effect of adrenaline and noradrenaline is possible.
Special instructions
In acute hemorrhoids the treatment has to be short-term.
Treatment of acute hemorrhoids can be carried out in a complex with other methods of treatment. In case symptoms do not disappear after the recommended course of treatment, it is necessary to consult with the expert who will pick up further therapy.
Presence of Ponso4R dye (E124) can lead ment of allergic manifestations.
Pregnancy and a lactation
Use during pregnancy is possible only |only| on doctor's orders when the expected advantage |self-interest| for mother exceeds potential risk for a fruit.
In pilot studies the teratogenic impact on a fruit was not revealed. So far in clinical practice there were no messages about cases of malformatsionny or fetotoksichesky action on a fruit at use of drug for pregnant women.
Due to the lack of data on penetration of drug into breast milk, administration of drug is not recommended to the feeding women.
There Is no feature of influence of drug on ability to run the vehicle or potentially dangerous mechanisms data on negative influence of drug on ability to run vehicles and other mechanisms
Overdose
Symptoms of overdose are not described.
A form of release and packing
On 15 or 18 tablets in planimetric cell packing from a film of polyvinylchloride and aluminum foil.
On 1, 2 and 4 (on 15 tablets) or on 1 (on 18 tablets) blister strip packagings together with the instruction for medical use place in a cardboard pack.
To Store storage conditions at a temperature not over 30C.
To store out of children's reach!
Not to apply a period of storage of 5 years after the expiration date specified on packing
Prescription status
Without prescription
the Producer Innotera Shuzi, Rue Rene Shantero, Shuzi-Sur-Cis, 41150, Valuar-sur-Cis, France
the Owner of the registration certificate
Innoter's Laboratory, France
the Name, the address and a contact information (phone, the fax, e-mail) of the organization in the territory of the Republic of Kazakhstan, the accepting claim (offer) on quality of medicines from consumers and responsible for post-registration observation of safety of medicine:
Representative office of Innotek Internasional Laboratory of S.A.S. in PK
050059, Republic of Kazakhstan, Almaty, Al-Farabi Ave., 17, Nurla Tau's business center, the block of 4 B, office 606, ph./fax: +7-727-311-09-71, +7-727-311-09-72, e-mail: innotech@innotech.kz
Related Products
